Home » Viollier to Offer Epigenomics' Colorectal Cancer Test

Viollier to Offer Epigenomics' Colorectal Cancer Test

Jun 23, 2009

NEW YORK (GenomeWeb News) – Swiss diagnostics lab Viollier has obtained rights to offer Epigenomics' molecular test for colorectal cancer detection as a service to patients in Europe beginning July 1.

Berlin-based Epigenomics said that the test is based on its mSEPT9 biomarker and is the first ever blood-based test for colorectal cancer to be offered in Europe. It said that it expects other diagnostic labs in Europe to offer mSEPT9 testing "in due course."

In addition, Epigenomics said that mSEPT9 testing in the US would initially be offered by Quest Diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Best Options

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

A Butterfly's Wings

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

This Week in PNAS

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Pathogen Tracking

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

What's Popular?

In Diagnostics

  1. Ambry Genetics, FDNA Ink Deal to Integrate Technologies

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.